BG106180A - Pharmaceutical composition containing sibutramine and orlistat - Google Patents

Pharmaceutical composition containing sibutramine and orlistat

Info

Publication number
BG106180A
BG106180A BG106180A BG10618001A BG106180A BG 106180 A BG106180 A BG 106180A BG 106180 A BG106180 A BG 106180A BG 10618001 A BG10618001 A BG 10618001A BG 106180 A BG106180 A BG 106180A
Authority
BG
Bulgaria
Prior art keywords
orlistat
pharmaceutical composition
composition containing
containing sibutramine
human
Prior art date
Application number
BG106180A
Other languages
Bulgarian (bg)
Inventor
David Heal
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG106180A publication Critical patent/BG106180A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

A method for the treatment of co-morbid conditions associated with obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula including enantiomers and pharmaceutically acceptable salts thereof, in which R1 and R2 are independently H or methyl, and a therapeutically effective amount of a compound of formula wherein the given compounds are administered simultaneously, separately or sequentially. 8 claims
BG106180A 1999-06-24 2001-12-04 Pharmaceutical composition containing sibutramine and orlistat BG106180A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
BG106180A true BG106180A (en) 2002-08-30

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106180A BG106180A (en) 1999-06-24 2001-12-04 Pharmaceutical composition containing sibutramine and orlistat

Country Status (21)

Country Link
EP (1) EP1187606A1 (en)
JP (1) JP2003503349A (en)
KR (1) KR20020015357A (en)
CN (1) CN1358092A (en)
AU (1) AU5533200A (en)
BG (1) BG106180A (en)
BR (1) BR0011880A (en)
CA (1) CA2375972A1 (en)
CZ (1) CZ20014613A3 (en)
GB (1) GB9914744D0 (en)
HK (1) HK1049278A1 (en)
HU (1) HUP0201878A3 (en)
IL (1) IL147079A0 (en)
MX (1) MXPA01012936A (en)
NO (1) NO20016224L (en)
PL (1) PL352402A1 (en)
RU (1) RU2229289C2 (en)
SK (1) SK18242001A3 (en)
TR (1) TR200103699T2 (en)
WO (1) WO2001000205A1 (en)
ZA (1) ZA200109989B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
EP1807063A2 (en) 2004-10-25 2007-07-18 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2663254C (en) * 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR20080046601A (en) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 Inclusion complex of sibutramine and beta-cyclodextrin
CN101890017A (en) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 Medicament composition containing sibutramine and stanin fat-reducing medicament and application thereof
MX336980B (en) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combination and composition for treating obesity.
CN104039753B (en) 2011-12-30 2016-09-14 雷维瓦药品公司 The compositions of phenylcycloalkyl methylamine derivative, synthesis and using method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
AU5533200A (en) 2001-01-31
CZ20014613A3 (en) 2003-04-16
CA2375972A1 (en) 2001-01-04
NO20016224L (en) 2002-02-12
CN1358092A (en) 2002-07-10
GB9914744D0 (en) 1999-08-25
ZA200109989B (en) 2003-02-26
HK1049278A1 (en) 2003-05-09
HUP0201878A3 (en) 2005-04-28
EP1187606A1 (en) 2002-03-20
RU2229289C2 (en) 2004-05-27
MXPA01012936A (en) 2004-04-21
KR20020015357A (en) 2002-02-27
JP2003503349A (en) 2003-01-28
TR200103699T2 (en) 2002-04-22
NO20016224D0 (en) 2001-12-19
BR0011880A (en) 2002-03-19
IL147079A0 (en) 2002-08-14
HUP0201878A2 (en) 2003-08-28
WO2001000205A1 (en) 2001-01-04
PL352402A1 (en) 2003-08-25
SK18242001A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
GB2254784B (en) Film-coated solid dosage form of anti-migraine drug
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
GEP20043324B (en) Purine Derivatives
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
LU91254I2 (en) Daptomycin and its pharmaceutically acceptable derivatives (cubicinr)
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
BG103945A (en) Derivatives of 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
EP0740650A4 (en) Codrugs as a method of controlled drug delivery
WO2005056524A3 (en) Therapeutic agents useful for treating pain
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
AU3850600A (en) Dalda analogs and their use
GB9305295D0 (en) Therapeutic compounds
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MX9605458A (en) Amide derivatives and their therapeutic use.
BG106209A (en) Therapeutic agents
WO2005055933A3 (en) Treatment of psoriasis with rosiglitazone
TW200510370A (en) Urea derivatives
MY133438A (en) Morpholinobenzamide salts
AP9801235A0 (en) Erythromycin derivatives.
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
MY126998A (en) Substituted pyrroles.